Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLBD5I)

Drug Name

LXE408 Drug Info

Synonyms

SCHEMBL16822697; HY-131350; CS-0133456; FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C2=NC=CC=C2C)=N1; 1799330-15-6; N-(4-Fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Visceral leishmaniasis	1F54.0	Phase 2	[1]

Cross-matching ID

PubChem CID: 118162630
TTD Drug ID: DMLBD5I

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leishmania major Proteasome (Leishm Proteasome)	TTSVQWU	Q4QH56_LEIMA; Q4Q1Q9_LEIMA	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of Novartis.
2	Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases. J Med Chem. 2020 Oct 8;63(19):10773-10781.